| Not Yet Recruiting | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Canc Limited Stage Small Cell Lung Cancer | Phase 3 | 2026-03-31 |
| Recruiting | Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptoma Chronic Heart Failure, Iron Deficiencies | Phase 3 | 2025-05-01 |
| Not Yet Recruiting | A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Malignant Lymphoma, Multiple Myeloma | Phase 4 | 2024-04-30 |
| Recruiting | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Extensive-stage Small-cell Lung Cancer | Phase 4 | 2023-10-18 |
| Recruiting | A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndro Beta Thalassemia Major Anemia, Myelodysplastic Syndrome | Phase 2 | 2023-09-04 |
| Recruiting | Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Iron Deficiency, Anaemia in Children | Phase 3 | 2022-11-28 |
| Completed | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric IBD | Phase 4 | 2018-05-23 |
| Completed | Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymal Iron Deficiency Anaemia, Iron Deficiency Anemia | Phase 3 | 2017-10-30 |
| Completed | Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymal Iron Deficiency Anaemia, Iron Deficiency Anemia | Phase 3 | 2017-10-24 |
| Completed | Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy. Iron Deficiency Anemia of Pregnancy | Phase 4 | 2017-07-11 |
| Completed | An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monof Iron Deficiency Anemia, Iron Deficiency Anaemia | Phase 3 | 2017-01-09 |
| Completed | Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®) Anemia, Deficiency Diseases, Anemia, Iron Deficiency | Phase 1 | 2017-01-06 |
| Completed | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease | Phase 3 | 2016-11-29 |
| Completed | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) Iron Deficiency Anaemia, Iron Deficiency Anemia | Phase 3 | 2016-11-08 |
| Withdrawn | IV Iron Treatment of Restless Legs Syndrome Restless Legs Syndrome | Phase 2 | 2015-01-01 |
| Completed | A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease | — | 2014-09-01 |
| Completed | IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron S Iron Deficiency Anaemia | Phase 3 | 2014-05-01 |
| Completed | Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®) Iron Deficiency Anemia | — | 2013-08-01 |
| Completed | A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Don Iron-deficiency | Phase 3 | 2013-06-01 |
| Completed | Treatment of Women After Severe Postpartum Haemorrhage Severe Postpartum Haemorrhage | Phase 3 | 2013-06-01 |
| Completed | Treatment of Women After Postpartum Haemorrhage Postpartum Haemorrhage | Phase 3 | 2013-06-01 |
| Completed | Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Di Inflammatory Bowel Disease | Phase 3 | 2012-05-01 |
| Completed | Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injectio Non-dialysis Dependent Chronic Kidney Disease | Phase 1 | 2012-03-01 |
| Completed | Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenou Patients With Chemotherapy Induced Anemia (CIA) | Phase 1 | 2012-03-01 |
| Completed | Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infu Inflammatory Bowel Disease | Phase 1 | 2012-02-01 |
| Completed | Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injectio Non-hematological Malignancies | Phase 1 | 2012-02-01 |
| Completed | A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-anaemic Patients Undergoing Cardiac Surgery | Phase 3 | 2012-01-01 |
| Completed | Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections Chronic Kidney Disease | Phase 1 | 2011-10-01 |
| Completed | A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Re Chronic Kidney Disease Stage 5 (Dialysis Dependent) | Phase 3 | 2011-06-01 |
| Completed | Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel D Inflammatory Bowel Disease, Anaemia | Phase 3 | 2011-06-01 |
| Completed | A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating A Non-myeloid Malignancies, Chemotherapy Induced Anaemia | Phase 3 | 2010-10-01 |
| Completed | Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anae Iron Deficiency Anemia, Chronic Kidney Disease | Phase 3 | 2010-04-01 |
| Completed | Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia Inflammatory Bowel Disease | Phase 3 | 2009-10-01 |
| Completed | A Study of Iron Oligosaccharide in CHF Patients Heart Failure, Congestive | Phase 3 | 2007-06-01 |
| Completed | A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients Chronic Kidney Disease, Anemia, Iron-Deficiency | Phase 3 | 2007-05-01 |
| Withdrawn | A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo Iron Deficiency Anemia | Phase 3 | — |